正交SARS-CoV-2血清學檢測揭示持久的體液免疫
作者：
小柯機器人發布時間：2020/10/15 15:39:06
美國亞利桑那大學Deepta Bhattacharya、Janko Nikolich-ugich等研究人員合作發現，正交SARS-CoV-2血清學檢測可監測低患病率社區並揭示持久的體液免疫。相關論文於2020年10月13日在線發表在《免疫》雜誌上。
研究人員進行了一項血清學研究，以定義針對SARS-CoV-2的免疫相關性。相對於輕度COVID-19病例，重症患者表現出較高的病毒中和效價和針對核衣殼（N）和刺突蛋白受體結合域（RBD）的抗體。年齡和性別發揮的作用較小。PCR確認後2周，包括無症狀個體在內的所有病例均發生血清轉化。發病後5-7個月仍可檢測到突刺RBD和S2的中和抗體，而α-N滴度卻降低了。
對5882個本地社區成員的測試顯示，只有1個樣品對RBD和S2具有血清反應性，但缺少中和抗體。僅使用RBD或S2不能達到這種保真度。因此，包含多個獨立的測定方法提高了低血清陽性率社區中抗體測試的準確性，並揭示了取決於抗原的抗體動力學差異。研究人員認為，SARS-CoV-2感染後至少5-7個月內能夠穩定產生中和抗體。
附：英文原文
Title: Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low Prevalence Communities and Reveal Durable Humoral Immunity.
Author: Tyler J. Ripperger, Jennifer L. Uhrlaub, Makiko Watanabe, Rachel Wong, Yvonne Castaneda, Hannah A. Pizzato, Mallory R. Thompson, Christine Bradshaw, Craig C. Weinkauf, Christian Bime, Heidi L. Erickson, Kenneth Knox, Billie Bixby, Sairam Parthasarathy, Sachin Chaudhary, Bhupinder Natt, Elaine Cristan, Tammer El Aini, Franz Rischard, Janet Campion, Madhav Chopra, Michael Insel, Afshin Sam, James L. Knepler, Andrew P. Capaldi, Catherine M. Spier, Michael D. Dake, Taylor Edwards, Matthew E. Kaplan, Serena Jain Scott, Cameron Hypes, Jarrod Mosier, David T. Harris, Bonnie J. LaFleur, Ryan Sprissler, Janko Nikolich-ugich, Deepta Bhattacharya
Issue&Volume: 2020-10-13
Abstract: We conducted a serological study to define correlates of immunity against SARS-CoV-2. Relative to mild COVID-19 cases, individuals with severe disease exhibited elevated virus-neutralizing titers and antibodies against nucleocapsid (N) and the receptor binding domain (RBD) of spike protein. Age and sex played lesser roles. All cases, including asymptomatic individuals, seroconverted by 2 weeks post-PCR confirmation. Spike RBD and S2 and neutralizing antibodies remained detectable through 5-7 months post-onset, whereas α-N titers diminished. Testing of 5882 members of the local community revealed only 1 sample with seroreactivity to both RBD and S2 that lacked neutralizing antibodies. This fidelity could not be achieved with either RBD or S2 alone. Thus, inclusion of multiple independent assays improved the accuracy of antibody tests in low seroprevalence communities and revealed differences in antibody kinetics depending on the antigen. We conclude that neutralizing antibodies are stably produced for at least 5-7 months after SARS-CoV-2 infection.
DOI: 10.1016/j.immuni.2020.10.004
Source: https://www.cell.com/immunity/fulltext/S1074-7613(20)30445-3